Skip to main content

NYSE:DGX - Quest Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $139.75
  • Forecasted Upside: 0.58 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$138.95
▲ +0.56 (0.40%)
1 month | 3 months | 12 months
Get New Quest Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DGX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$139.75
▲ +0.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $139.75, with a high forecast of $158.00 and a low forecast of $120.00. The average price target represents a 0.58% upside from the last price of $138.95.

Buy

The current consensus among 12 polled investment analysts is to buy stock in Quest Diagnostics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 1 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 1 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 1 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2021UBS GroupUpgradeNeutral ➝ Buy$135.00 ➝ $158.00High
i
3/18/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$137.00Low
i
3/18/2021Morgan StanleyBoost Price TargetEqual Weight$130.00 ➝ $136.00Low
i
3/12/2021Morgan StanleyBoost Price TargetEqual Weight$130.00 ➝ $136.00Low
i
3/12/2021Robert W. BairdDowngradeOutperform ➝ Neutral$137.00Low
i
1/29/2021CitigroupBoost Price Target$151.00 ➝ $158.00Low
i
12/17/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
10/26/2020MizuhoBoost Price TargetBuy$144.00 ➝ $149.00Medium
i
10/23/2020Wells Fargo & CompanyReiterated RatingHoldLow
i
Rating by Dan Leonard at Wells Fargo & Company
10/21/2020ArgusUpgradeHold ➝ Buy$135.00Medium
i
10/14/2020Jefferies Financial GroupBoost Price TargetBuy$125.00 ➝ $134.00Medium
i
7/24/2020Deutsche Bank AktiengesellschaftBoost Price TargetTop Pick ➝ Buy$140.00 ➝ $150.00Medium
i
Rating by Pito Chickering at Deutsche Bank Aktiengesellschaft
7/24/2020MizuhoBoost Price TargetBuy$114.00 ➝ $144.00Medium
i
7/24/2020CitigroupBoost Price TargetBuy$130.00 ➝ $151.00Medium
i
7/14/2020Credit Suisse GroupBoost Price TargetNeutral$126.00 ➝ $128.00High
i
7/14/2020Bank of AmericaUpgradeNeutral ➝ Buy$142.00High
i
6/9/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$90.00 ➝ $120.00Low
i
Rating by Dan Leonard at Wells Fargo & Company
6/1/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$140.00High
i
5/21/2020SunTrust BanksBoost Price TargetHold$110.00 ➝ $130.00Low
i
5/20/2020Morgan StanleyBoost Price TargetOverweight$139.00 ➝ $146.00Medium
i
5/5/2020UBS GroupBoost Price TargetNeutral$106.00 ➝ $111.00Low
i
4/30/2020Bank of AmericaBoost Price TargetNeutral$105.00 ➝ $120.00Low
i
Rating by Derik De Bruin at Bank of America Co.
4/28/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$95.00 ➝ $139.00High
i
4/27/2020Wolfe ResearchUpgradeUnderperform ➝ Market Perform$116.00Medium
i
4/27/2020CitigroupUpgradeNeutral ➝ Buy$113.00 ➝ $130.00High
i
4/24/2020Credit Suisse GroupReiterated RatingHold$100.00Low
i
4/23/2020JPMorgan Chase & Co.Boost Price TargetNeutral$87.00 ➝ $111.00Medium
i
4/23/2020SunTrust BanksBoost Price TargetHold$100.00 ➝ $110.00Low
i
4/23/2020BarclaysBoost Price TargetEqual Weight$93.00 ➝ $99.00Low
i
Rating by Jack Meehan at Barclays PLC
4/23/2020Wells Fargo & CompanyBoost Price TargetUnderweight$80.00 ➝ $90.00Low
i
4/22/2020CfraDowngradeStrong-Buy ➝ Hold$140.00 ➝ $106.00Medium
i
4/16/2020MizuhoLower Price TargetBuy$110.00 ➝ $106.00Medium
i
4/13/2020SunTrust BanksLower Price TargetHold$115.00 ➝ $100.00Low
i
4/2/2020JPMorgan Chase & Co.Lower Price TargetNeutral$99.00 ➝ $87.00Low
i
3/30/2020Wells Fargo & CompanyLower Price TargetUnderweight$100.00 ➝ $80.00Low
i
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00High
i
3/26/2020BarclaysLower Price TargetEqual Weight$106.00 ➝ $93.00Low
i
Rating by Jack Meehan at Barclays PLC
3/5/2020CfraUpgradeHold ➝ Strong-Buy$116.00 ➝ $140.00Low
i
2/10/2020MizuhoBoost Price TargetBuy$116.00 ➝ $122.00Low
i
2/3/2020CitigroupBoost Price TargetNeutral$110.00 ➝ $113.00Low
i
1/31/2020Bank of AmericaBoost Price TargetNeutral$110.00 ➝ $116.00Low
i
Rating by Derik De Bruin at Bank of America Co.
1/31/2020Robert W. BairdBoost Price TargetOutperform$113.00 ➝ $118.00Low
i
1/30/2020Piper SandlerBoost Price TargetHold$102.00 ➝ $107.00Low
i
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$100.00Low
i
1/7/2020BarclaysDowngradeOverweight ➝ Equal Weight$106.00Medium
i
1/3/2020Bank of AmericaDowngradeNeutral ➝ UnderperformLow
i
Rating by Derik De Bruin at Bank of America Co.
12/19/2019Bank of AmericaUpgradeUnderperform ➝ Neutral$94.00 ➝ $110.00Low
i
10/23/2019Canaccord GenuityReiterated RatingBuy$113.00Medium
i
10/21/2019UBS GroupLower Price TargetNeutral$103.00 ➝ $102.00Low
i
8/23/2019Morgan StanleyBoost Price TargetOverweight$111.00 ➝ $121.00High
i
8/8/2019Evercore ISIReiterated RatingBuy$108.00Low
i
7/24/2019JPMorgan Chase & Co.Boost Price TargetNeutral$100.00 ➝ $111.00Low
i
7/24/2019Morgan StanleyBoost Price TargetOverweight$104.00 ➝ $111.00Low
i
7/24/2019Canaccord GenuityBoost Price TargetBuy$108.00 ➝ $112.00Low
i
7/24/2019Credit Suisse GroupBoost Price TargetNeutral$99.00 ➝ $105.00Low
i
7/15/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$90.00 ➝ $85.00High
i
5/20/2019MizuhoSet Price TargetBuy$110.00Low
i
Rating by Ann Hynes at Mizuho
4/25/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$98.00 ➝ $104.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
4/24/2019UBS GroupBoost Price TargetNeutral$91.00 ➝ $99.00Low
i
Rating by Kevin Caliendo at UBS Group AG
4/24/2019CitigroupBoost Price TargetNeutral$93.00 ➝ $102.00Medium
i
4/24/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$97.00 ➝ $103.00Medium
i
4/2/2019Wolfe ResearchInitiated CoverageUnderperformLow
i
4/2/2019Jefferies Financial GroupUpgradeHold ➝ Buy$93.00 ➝ $107.00Low
i
3/18/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$101.00 ➝ $91.00Low
i
2/19/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$103.00 ➝ $101.00Low
i
2/18/2019Canaccord GenuityReiterated RatingBuy$97.00Low
i
2/15/2019MizuhoSet Price TargetBuy$106.00Low
i
Rating by Ann Hynes at Mizuho
2/15/2019UBS GroupSet Price TargetHold$91.00Low
i
Rating by Kevin Caliendo at UBS Group AG
2/15/2019BarclaysReiterated RatingBuy$114.00Low
i
2/14/2019Piper Jaffray CompaniesLower Price TargetNeutral$110.00 ➝ $100.00High
i
1/31/2019ArgusDowngradeBuy ➝ HoldMedium
i
Rating by Jasper Hellweg at Argus
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$90.00Low
i
1/3/2019Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
i
12/20/2018Morgan StanleySet Price TargetBuy$101.00Medium
i
Rating by Ricky Goldwasser at Morgan Stanley
12/9/2018The Goldman Sachs GroupLower Price TargetBuy ➝ Neutral$110.00 ➝ $90.00Low
i
Rating by Patrick B Donnelly at The Goldman Sachs Group, Inc.
12/3/2018SunTrust BanksLower Price TargetHold ➝ Positive$96.00Medium
i
12/3/2018Bank of AmericaDowngradeBuy ➝ NeutralMedium
i
12/2/2018Credit Suisse GroupReiterated RatingBuy$121.00Medium
i
11/30/2018BarclaysLower Price TargetOverweight ➝ Overweight$125.00 ➝ $117.00Low
i
11/30/2018Craig HallumReiterated RatingHold$94.00Medium
i
11/30/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$121.00 ➝ $103.00Medium
i
11/30/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$120.00 ➝ $107.00Medium
i
11/30/2018Canaccord GenuityReiterated RatingBuy$98.00Low
i
11/30/2018The Goldman Sachs GroupDowngradeBuy ➝ Neutral$110.00 ➝ $90.00Low
i
Rating by Patrick B Donnelly at The Goldman Sachs Group, Inc.
11/20/2018MizuhoSet Price TargetBuy$108.00Medium
i
Rating by Ann Hynes at Mizuho
10/24/2018ArgusSet Price TargetBuy$106.00Low
i
Rating by Jasper Hellweg at Argus
10/24/2018BarclaysLower Price TargetOverweight ➝ Overweight$130.00 ➝ $125.00Medium
i
10/24/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$128.00 ➝ $121.00High
i
10/24/2018CitigroupLower Price TargetNeutral ➝ Neutral$112.00 ➝ $104.00High
i
10/24/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$118.00 ➝ $105.00High
i
10/24/2018JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$114.00 ➝ $107.00High
i
10/23/2018William BlairReiterated RatingOutperformLow
i
Rating by M. Larew at William Blair
10/19/2018Bank of AmericaInitiated CoverageBuy ➝ BuyLow
i
9/24/2018Credit Suisse GroupBoost Price TargetOutperform$121.00 ➝ $128.00Low
i
9/14/2018ArgusSet Price TargetBuy$116.00 ➝ $120.00Low
i
Rating by Jasper Hellweg at Argus
7/10/2018Evercore ISIUpgradeIn-Line ➝ Outperform$103.00High
i
6/27/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$108.00High
i
6/25/2018BarclaysUpgradeEqual Weight ➝ Overweight$120.00 ➝ $130.00High
i
6/8/2018William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by Amanda Murphy at William Blair
5/29/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$120.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
5/28/2018BarclaysReiterated RatingHold$120.00Low
i
5/25/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$118.00 ➝ $121.00Low
i
5/25/2018MizuhoReiterated RatingBuyHigh
i
Rating by Ann Hynes at Mizuho
5/1/2018Robert W. BairdUpgradeNeutral ➝ Outperform$115.00Medium
i
3/19/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$113.00 ➝ $115.00Low
i
3/14/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$103.00Low
i
3/7/2018ArgusUpgradeHold ➝ Buy$104.14 ➝ $116.00Low
i
2/13/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$107.00Medium
i
2/2/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$107.00Low
i
2/1/2018Piper Jaffray CompaniesReiterated RatingHold$110.00Low
i
1/29/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$117.00Medium
i
1/24/2018MizuhoSet Price TargetBuy$113.00Low
i
Rating by Ann Hynes at Mizuho
1/16/2018Canaccord GenuityReiterated RatingBuy$110.00Low
i
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$103.00Low
i
11/25/2017Jefferies Financial GroupSet Price TargetHold$98.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/27/2017KeyCorpReiterated RatingHoldN/A
i
10/26/2017Canaccord GenuityBoost Price TargetBuy$100.00 ➝ $105.00N/A
i
10/20/2017Wells Fargo & CompanyLower Price TargetMarket Perform$88.00 ➝ $86.00N/A
i
10/20/2017CitigroupLower Price TargetNeutral$110.00 ➝ $98.00N/A
i
10/19/2017MizuhoSet Price TargetBuy ➝ Buy$122.00 ➝ $103.00N/A
i
Rating by Ann Hynes at Mizuho
10/17/2017Craig HallumReiterated RatingHold$110.00 ➝ $100.00N/A
i
10/15/2017SunTrust BanksSet Price TargetHold$105.00N/A
i
Rating by David S Macdonald at SunTrust Banks, Inc.
10/12/2017Wells Fargo & CompanyInitiated CoverageUnderperform ➝ Market Perform$88.00N/A
i
10/10/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$121.00 ➝ $113.00N/A
i
9/28/2017Credit Suisse GroupLower Price TargetNeutral$110.00 ➝ $99.00Low
i
9/25/2017Raymond JamesReiterated RatingOutperform ➝ Market PerformHigh
i
9/13/2017Canaccord GenuityReiterated RatingBuy$118.00Medium
i
8/10/2017Morgan StanleyBoost Price TargetUnderweight$87.00 ➝ $92.00Low
i
7/25/2017Bank of AmericaUpgradeNeutral ➝ Buy$111.00 ➝ $118.00Medium
i
7/25/2017Piper Jaffray CompaniesBoost Price TargetNeutral$107.00High
i
7/19/2017BarclaysReiterated RatingHold$110.00Low
i
7/13/2017Credit Suisse GroupReiterated RatingNeutral$83.00 ➝ $110.00Low
i
7/6/2017UBS GroupBoost Price TargetBuy$115.00 ➝ $123.00N/A
i
6/28/2017Evercore ISIReiterated RatingIn-Line$104.50Low
i
6/13/2017Canaccord GenuityReiterated RatingBuy$118.00Low
i
Rating by Mark Massaro at Canaccord Genuity
6/5/2017MizuhoBoost Price TargetBuy ➝ Buy$115.00 ➝ $122.00Low
i
5/28/2017Bank of AmericaReiterated RatingNeutral$105.00 ➝ $110.00Low
i
5/12/2017ArgusInitiated CoverageHold ➝ Hold$102.00Low
i
4/26/2017MizuhoBoost Price TargetBuy$110.00 ➝ $115.00Low
i
4/25/2017Canaccord GenuityBoost Price TargetBuy$102.00 ➝ $115.00Low
i
Rating by Mark Massaro at Canaccord Genuity
4/25/2017UBS GroupReiterated RatingBuy$102.00 ➝ $115.00N/A
i
Rating by A.J. Rice at UBS Group AG
4/24/2017Evercore ISIReiterated RatingIn-Line$102.00 ➝ $104.50Low
i
4/23/2017BarclaysReiterated RatingEqual Weight$98.00 ➝ $100.00Low
i
Rating by Jack Meehan at Barclays PLC
4/23/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$108.00 ➝ $115.00Low
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
4/21/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$116.00Low
i
4/21/2017UBS GroupUpgradeMarket Perform ➝ OutperformN/A
i
Rating by A.J. Rice at UBS Group AG
4/14/2017MizuhoReiterated RatingBuy$103.00 ➝ $90.00N/A
i
4/12/2017(FBRC)Boost Price TargetOutperform$103.00 ➝ $110.00Low
i
3/16/2017Bank of AmericaUpgradeUnderperform ➝ Neutral$85.00 ➝ $103.00Medium
i
3/16/2017Jefferies Financial GroupReiterated RatingHold$96.00Medium
i
3/14/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$113.00Low
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
3/7/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$92.00 ➝ $98.00N/A
i
Rating by Jack Meehan at Barclays PLC
1/31/2017UBS GroupUpgradeNeutral ➝ BuyN/A
i
Rating by A.J. Rice at UBS Group AG
1/27/2017Jefferies Financial GroupBoost Price TargetHold$86.00 ➝ $96.00N/A
i
1/26/2017Canaccord GenuitySet Price TargetBuy$102.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$108.00N/A
i
1/17/2017Canaccord GenuitySet Price TargetBuy$90.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/3/2017UBS GroupSet Price TargetBuy$90.00 ➝ $102.00N/A
i
Rating by A.J. Rice at UBS Group AG
12/12/2016The Goldman Sachs GroupUpgradeNeutral ➝ Buy$102.00N/A
i
11/30/2016UBS GroupUpgradeNeutral ➝ Buy$90.00N/A
i
Rating by A.J. Rice at UBS Group AG
11/30/2016MizuhoReiterated RatingNeutral$88.00N/A
i
11/14/2016Canaccord GenuitySet Price TargetBuy$90.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
11/14/2016BarclaysSet Price TargetHold$85.00N/A
i
Rating by Jack Meehan at Barclays PLC
11/14/2016Bank of AmericaReiterated RatingSell$78.00N/A
i
11/14/2016UBS GroupUpgradeNeutral ➝ Buy$88.00 ➝ $90.00N/A
i
10/21/2016MizuhoBoost Price TargetNeutral$86.00 ➝ $88.00N/A
i
Rating by Ann Hynes at Mizuho
10/20/2016Canaccord GenuitySet Price TargetBuy$90.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
9/14/2016Canaccord GenuitySet Price TargetBuy$90.00N/A
i
Rating by mark massaro at Canaccord Genuity
9/13/2016MizuhoReiterated RatingNeutral$86.00N/A
i
Rating by Ann Hynes at Mizuho
9/9/2016CitigroupInitiated CoverageNeutral$86.00N/A
i
8/31/2016MizuhoDowngradeBuy ➝ Neutral$84.00 ➝ $86.00N/A
i
Rating by Ann Hynes at Mizuho
8/22/2016UBS GroupReiterated RatingHoldN/A
i
7/26/2016UBS GroupReiterated RatingHold$84.00N/A
i
7/24/2016Evercore ISIReiterated RatingHold$78.50 ➝ $89.50N/A
i
7/22/2016Jefferies Financial GroupBoost Price TargetHold$75.00 ➝ $86.00N/A
i
6/24/2016Jyske BankDowngradeNeutral ➝ SellN/A
i
6/22/2016UBS GroupInitiated CoverageHoldN/A
i
6/7/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by Ricky Goldwasser at Morgan Stanley
6/3/2016MizuhoReiterated RatingBuy$84.00N/A
i
Rating by Ann Hynes at Mizuho
5/24/2016Credit Suisse GroupReiterated RatingHoldN/A
i
Rating by Robert Willoughby at Credit Suisse Group AG
5/22/2016KeyCorpReiterated RatingHoldN/A
i
5/16/2016Robert W. BairdReiterated RatingHoldN/A
i
Rating by Whit Mayo at Robert W. Baird
(Data available from 5/9/2016 forward)
Quest Diagnostics logo
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More

Today's Range

Now: $138.95
$138.65
$140.64

50 Day Range

MA: $129.56
$124.26
$138.39

52 Week Range

Now: $138.95
$103.26
$140.64

Volume

1,264,901 shs

Average Volume

1,319,384 shs

Market Capitalization

$18.15 billion

P/E Ratio

17.18

Dividend Yield

1.79%

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Quest Diagnostics?

The following sell-side analysts have issued research reports on Quest Diagnostics in the last twelve months: Argus, Bank of America Co., Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Mizuho, Morgan Stanley, Robert W. Baird, SunTrust Banks, Inc., TheStreet, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for DGX.

What is the current price target for Quest Diagnostics?

12 Wall Street analysts have set twelve-month price targets for Quest Diagnostics in the last year. Their average twelve-month price target is $139.75, suggesting a possible upside of 0.6%. UBS Group AG has the highest price target set, predicting DGX will reach $158.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $120.00 for Quest Diagnostics in the next year.
View the latest price targets for DGX.

What is the current consensus analyst rating for Quest Diagnostics?

Quest Diagnostics currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DGX will outperform the market and that investors should add to their positions of Quest Diagnostics.
View the latest ratings for DGX.

What other companies compete with Quest Diagnostics?

Other companies that are similar to Quest Diagnostics include Laboratory Co. of America, DaVita, Amedisys, Chemed, R1 RCM, LHC Group, AMN Healthcare Services, MEDNAX, CorVel, Tivity Health and Cross Country Healthcare.

How do I contact Quest Diagnostics' investor relations team?

Quest Diagnostics' physical mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company's listed phone number is 973-520-2700 and its investor relations email address is [email protected] The official website for Quest Diagnostics is www.questdiagnostics.com.